1 | range | 33,574 |
2 | synonym | 22 |
3 | skyscan | 18 |
4 | pe-formula | 12 |
5 | bvwi | 8 |
6 | 'play | 7 |
7 | baricity | 6 |
8 | cttad | 5 |
9 | scion | 5 |
10 | copepoda | 4 |
11 | icd-code | 4 |
12 | idella | 4 |
13 | neotyphodium | 4 |
14 | parabola | 4 |
15 | spate | 4 |
16 | teqs | 4 |
17 | zmax | 4 |
18 | 5'nc | 3 |
19 | 6a-c | 3 |
20 | amphipoda | 3 |
21 | cter | 3 |
22 | decaocto | 3 |
23 | depcat | 3 |
24 | fs-pl | 3 |
25 | kin-com | 3 |
26 | macti | 3 |
27 | mev90 | 3 |
28 | n/d | 3 |
29 | ptpb | 3 |
30 | r2-r1 | 3 |
31 | t-nnt | 3 |
32 | 'analysis | 2 |
33 | 18-70years | 2 |
34 | 2791 | 2 |
35 | 3.5h/d | 2 |
36 | 4.577 | 2 |
37 | beta-coefficients | 2 |
38 | biosilicate® | 2 |
39 | breakfast/fasting | 2 |
40 | d58-value | 2 |
41 | delta-gap | 2 |
42 | deltari | 2 |
43 | dose/intensity | 2 |
44 | focr | 2 |
45 | frequency/quantity | 2 |
46 | glareolus | 2 |
47 | ham-d-17-score | 2 |
48 | iia- | 2 |
49 | lv-sf | 2 |
50 | mmoo4 | 2 |
51 | mwtp | 2 |
52 | na-salt | 2 |
53 | or4th | 2 |
54 | paga | 2 |
55 | patagonicus | 2 |
56 | pmnt/epoxy | 2 |
57 | pre-oxidation | 2 |
58 | roc-area | 2 |
59 | sham-icsi | 2 |
60 | suppleness | 2 |
61 | synchroniser | 2 |
62 | teacabts | 2 |
63 | tfz | 2 |
64 | transience | 2 |
65 | turtur | 2 |
66 | u-point | 2 |
67 | voltage-dependency | 2 |
68 | δzbmi | 2 |
69 | 'evacuation | 1 |
70 | 'stage* | 1 |
71 | +9.4/h | 1 |
72 | +9.41 | 1 |
73 | -90mg/g | 1 |
74 | .683 | 1 |
75 | /composition | 1 |
76 | 0-120° | 1 |
77 | 0.004-0.024 | 1 |
78 | 0.1cc/kg/6h | 1 |
79 | 1-hour/wk | 1 |
80 | 1.507±0.110 | 1 |
81 | 1.623±0.243 | 1 |
82 | 1.7g | 1 |
83 | 10.600 | 1 |
84 | 11.535 | 1 |
85 | 122- | 1 |
86 | 12–13 | 1 |
87 | 1750-19950iu | 1 |
88 | 19905 | 1 |
89 | 1mol/l | 1 |
90 | 1½h/week | 1 |
91 | 2.5:2.5 | 1 |
92 | 2.6iu/week/kg/gram | 1 |
93 | 23.9+/-4.1 | 1 |
94 | 24.6±3.8y | 1 |
95 | 25.2g | 1 |
96 | 26.4years | 1 |
97 | 27.3±7.4y | 1 |
98 | 29/179 | 1 |
99 | 3-4cm | 1 |
100 | 3.451 | 1 |
101 | 31±5year | 1 |
102 | 36.5±3.5weeks | 1 |
103 | 36.6±1.7year | 1 |
104 | 36.7weeks | 1 |
105 | 38.19+/-11.8 | 1 |
106 | 38±2years | 1 |
107 | 39/68 | 1 |
108 | 4.2±standard | 1 |
109 | 40.9years | 1 |
110 | 41,183 | 1 |
111 | 41±2year | 1 |
112 | 42,8±16,8 | 1 |
113 | 46+/-9 | 1 |
114 | 46.6±1.0 | 1 |
115 | 47,271 | 1 |
116 | 5,018 | 1 |
117 | 5.101 | 1 |
118 | 5.502 | 1 |
119 | 50p | 1 |
120 | 51,511 | 1 |
121 | 54±3years | 1 |
122 | 56-77years | 1 |
123 | 56.2±9.4years | 1 |
124 | 5722 | 1 |
125 | 58.6±7.1 | 1 |
126 | 59.9±12.6 | 1 |
127 | 59±14years | 1 |
128 | 60±1years | 1 |
129 | 61.0+/-9.6 | 1 |
130 | 63.6years | 1 |
131 | 63/815 | 1 |
132 | 65±10years | 1 |
133 | 66.0+/-9.3 | 1 |
134 | 66.1±6.4 | 1 |
135 | 68.8±13.4 | 1 |
136 | 68±10years | 1 |
137 | 7,972 | 1 |
138 | 7.571 | 1 |
139 | 7108 | 1 |
140 | 72±1years | 1 |
141 | 7445 | 1 |
142 | 79.06 | 1 |
143 | 8.273 | 1 |
144 | 9,3g | 1 |
145 | 9.68g | 1 |
146 | a6141115 | 1 |
147 | adjusted-prevalence | 1 |
148 | afferentation | 1 |
149 | airbursts/impacts | 1 |
150 | alexandrinus | 1 |
151 | amino-terminal-propeptide | 1 |
152 | areas/targets | 1 |
153 | athf | 1 |
154 | bdi= | 1 |
155 | bioavilaibility | 1 |
156 | bipartition | 1 |
157 | block-size | 1 |
158 | c16:0,18:2 | 1 |
159 | checkbook | 1 |
160 | dead-band | 1 |
161 | diklofenak | 1 |
162 | endothelisation | 1 |
163 | energy-gap | 1 |
164 | ergonomics-evaluation | 1 |
165 | exponentiation | 1 |
166 | expression/phosphorylation | 1 |
167 | fiber-guided | 1 |
168 | funding*location | 1 |
169 | group-65-79 | 1 |
170 | hekc | 1 |
171 | htvs | 1 |
172 | i2-values | 1 |
173 | intent-to-treat/time-to-loss | 1 |
174 | ispsma1 | 1 |
175 | lsr=stiffness | 1 |
176 | monohydrazone | 1 |
177 | mrtvs | 1 |
178 | mufa∶pufa | 1 |
179 | navigated=67 | 1 |
180 | non-universality | 1 |
181 | nonintersections | 1 |
182 | number/intensity | 1 |
183 | ofisoleucine | 1 |
184 | ovitrelle | 1 |
185 | pegl-1 | 1 |
186 | prevalemce | 1 |
187 | prospect-prevention | 1 |
188 | pulse-pressure | 1 |
189 | quenching-method | 1 |
190 | range= | 1 |
191 | range=1.57 | 1 |
192 | reflor | 1 |
193 | regulus | 1 |
194 | resistance/loss | 1 |
195 | s_tudy | 1 |
196 | severity/duration | 1 |
197 | survival/loss | 1 |
198 | taw | 1 |
199 | te/tm/tr | 1 |
200 | teacdpph | 1 |
201 | tizanidine® | 1 |
202 | toe-box | 1 |
203 | updrs-change | 1 |
204 | vecuronium-delay | 1 |
205 | winquist | 1 |
206 | ±s.d. | 1 |
207 | δmpef | 1 |
208 | λ= | 1 |
209 | ‘paradigm’ | 1 |
210 | ≈bottom | 1 |
211 | ≥39°c/102.2°f | 1 |
1 | 'analysis | 2 |
2 | 'evacuation | 1 |
3 | 'play | 7 |
4 | 'stage* | 1 |
5 | +9.4/h | 1 |
6 | +9.41 | 1 |
7 | -90mg/g | 1 |
8 | .683 | 1 |
9 | /composition | 1 |
10 | 0-120° | 1 |
11 | 0.004-0.024 | 1 |
12 | 0.1cc/kg/6h | 1 |
13 | 1-hour/wk | 1 |
14 | 1.507±0.110 | 1 |
15 | 1.623±0.243 | 1 |
16 | 1.7g | 1 |
17 | 10.600 | 1 |
18 | 11.535 | 1 |
19 | 122- | 1 |
20 | 12–13 | 1 |
21 | 1750-19950iu | 1 |
22 | 18-70years | 2 |
23 | 19905 | 1 |
24 | 1mol/l | 1 |
25 | 1½h/week | 1 |
26 | 2.5:2.5 | 1 |
27 | 2.6iu/week/kg/gram | 1 |
28 | 23.9+/-4.1 | 1 |
29 | 24.6±3.8y | 1 |
30 | 25.2g | 1 |
31 | 26.4years | 1 |
32 | 27.3±7.4y | 1 |
33 | 2791 | 2 |
34 | 29/179 | 1 |
35 | 3-4cm | 1 |
36 | 3.451 | 1 |
37 | 3.5h/d | 2 |
38 | 31±5year | 1 |
39 | 36.5±3.5weeks | 1 |
40 | 36.6±1.7year | 1 |
41 | 36.7weeks | 1 |
42 | 38.19+/-11.8 | 1 |
43 | 38±2years | 1 |
44 | 39/68 | 1 |
45 | 4.2±standard | 1 |
46 | 4.577 | 2 |
47 | 40.9years | 1 |
48 | 41,183 | 1 |
49 | 41±2year | 1 |
50 | 42,8±16,8 | 1 |
51 | 46+/-9 | 1 |
52 | 46.6±1.0 | 1 |
53 | 47,271 | 1 |
54 | 5'nc | 3 |
55 | 5,018 | 1 |
56 | 5.101 | 1 |
57 | 5.502 | 1 |
58 | 50p | 1 |
59 | 51,511 | 1 |
60 | 54±3years | 1 |
61 | 56-77years | 1 |
62 | 56.2±9.4years | 1 |
63 | 5722 | 1 |
64 | 58.6±7.1 | 1 |
65 | 59.9±12.6 | 1 |
66 | 59±14years | 1 |
67 | 60±1years | 1 |
68 | 61.0+/-9.6 | 1 |
69 | 63.6years | 1 |
70 | 63/815 | 1 |
71 | 65±10years | 1 |
72 | 66.0+/-9.3 | 1 |
73 | 66.1±6.4 | 1 |
74 | 68.8±13.4 | 1 |
75 | 68±10years | 1 |
76 | 6a-c | 3 |
77 | 7,972 | 1 |
78 | 7.571 | 1 |
79 | 7108 | 1 |
80 | 72±1years | 1 |
81 | 7445 | 1 |
82 | 79.06 | 1 |
83 | 8.273 | 1 |
84 | 9,3g | 1 |
85 | 9.68g | 1 |
86 | a6141115 | 1 |
87 | adjusted-prevalence | 1 |
88 | afferentation | 1 |
89 | airbursts/impacts | 1 |
90 | alexandrinus | 1 |
91 | amino-terminal-propeptide | 1 |
92 | amphipoda | 3 |
93 | areas/targets | 1 |
94 | athf | 1 |
95 | baricity | 6 |
96 | bdi= | 1 |
97 | beta-coefficients | 2 |
98 | bioavilaibility | 1 |
99 | biosilicate® | 2 |
100 | bipartition | 1 |
101 | block-size | 1 |
102 | breakfast/fasting | 2 |
103 | bvwi | 8 |
104 | c16:0,18:2 | 1 |
105 | checkbook | 1 |
106 | copepoda | 4 |
107 | cter | 3 |
108 | cttad | 5 |
109 | d58-value | 2 |
110 | dead-band | 1 |
111 | decaocto | 3 |
112 | delta-gap | 2 |
113 | deltari | 2 |
114 | depcat | 3 |
115 | diklofenak | 1 |
116 | dose/intensity | 2 |
117 | endothelisation | 1 |
118 | energy-gap | 1 |
119 | ergonomics-evaluation | 1 |
120 | exponentiation | 1 |
121 | expression/phosphorylation | 1 |
122 | fiber-guided | 1 |
123 | focr | 2 |
124 | frequency/quantity | 2 |
125 | fs-pl | 3 |
126 | funding*location | 1 |
127 | glareolus | 2 |
128 | group-65-79 | 1 |
129 | ham-d-17-score | 2 |
130 | hekc | 1 |
131 | htvs | 1 |
132 | i2-values | 1 |
133 | icd-code | 4 |
134 | idella | 4 |
135 | iia- | 2 |
136 | intent-to-treat/time-to-loss | 1 |
137 | ispsma1 | 1 |
138 | kin-com | 3 |
139 | lsr=stiffness | 1 |
140 | lv-sf | 2 |
141 | macti | 3 |
142 | mev90 | 3 |
143 | mmoo4 | 2 |
144 | monohydrazone | 1 |
145 | mrtvs | 1 |
146 | mufa∶pufa | 1 |
147 | mwtp | 2 |
148 | n/d | 3 |
149 | na-salt | 2 |
150 | navigated=67 | 1 |
151 | neotyphodium | 4 |
152 | non-universality | 1 |
153 | nonintersections | 1 |
154 | number/intensity | 1 |
155 | ofisoleucine | 1 |
156 | or4th | 2 |
157 | ovitrelle | 1 |
158 | paga | 2 |
159 | parabola | 4 |
160 | patagonicus | 2 |
161 | pe-formula | 12 |
162 | pegl-1 | 1 |
163 | pmnt/epoxy | 2 |
164 | pre-oxidation | 2 |
165 | prevalemce | 1 |
166 | prospect-prevention | 1 |
167 | ptpb | 3 |
168 | pulse-pressure | 1 |
169 | quenching-method | 1 |
170 | r2-r1 | 3 |
171 | range | 33,574 |
172 | range= | 1 |
173 | range=1.57 | 1 |
174 | reflor | 1 |
175 | regulus | 1 |
176 | resistance/loss | 1 |
177 | roc-area | 2 |
178 | s_tudy | 1 |
179 | scion | 5 |
180 | severity/duration | 1 |
181 | sham-icsi | 2 |
182 | skyscan | 18 |
183 | spate | 4 |
184 | suppleness | 2 |
185 | survival/loss | 1 |
186 | synchroniser | 2 |
187 | synonym | 22 |
188 | t-nnt | 3 |
189 | taw | 1 |
190 | te/tm/tr | 1 |
191 | teacabts | 2 |
192 | teacdpph | 1 |
193 | teqs | 4 |
194 | tfz | 2 |
195 | tizanidine® | 1 |
196 | toe-box | 1 |
197 | transience | 2 |
198 | turtur | 2 |
199 | u-point | 2 |
200 | updrs-change | 1 |
201 | vecuronium-delay | 1 |
202 | voltage-dependency | 2 |
203 | winquist | 1 |
204 | zmax | 4 |
205 | ±s.d. | 1 |
206 | δmpef | 1 |
207 | δzbmi | 2 |
208 | λ= | 1 |
209 | ‘paradigm’ | 1 |
210 | ≈bottom | 1 |
211 | ≥39°c/102.2°f | 1 |
1 | 'stage* | 1 |
2 | 122- | 1 |
3 | iia- | 2 |
4 | ±s.d. | 1 |
5 | 46.6±1.0 | 1 |
6 | 10.600 | 1 |
7 | 1.507±0.110 | 1 |
8 | mev90 | 3 |
9 | pegl-1 | 1 |
10 | 23.9+/-4.1 | 1 |
11 | 58.6±7.1 | 1 |
12 | 5.101 | 1 |
13 | 51,511 | 1 |
14 | +9.41 | 1 |
15 | 3.451 | 1 |
16 | 47,271 | 1 |
17 | 7.571 | 1 |
18 | 2791 | 2 |
19 | ispsma1 | 1 |
20 | r2-r1 | 3 |
21 | 5.502 | 1 |
22 | 5722 | 1 |
23 | 7,972 | 1 |
24 | c16:0,18:2 | 1 |
25 | 66.0+/-9.3 | 1 |
26 | 12–13 | 1 |
27 | 1.623±0.243 | 1 |
28 | 8.273 | 1 |
29 | 41,183 | 1 |
30 | .683 | 1 |
31 | 68.8±13.4 | 1 |
32 | 66.1±6.4 | 1 |
33 | 0.004-0.024 | 1 |
34 | mmoo4 | 2 |
35 | 2.5:2.5 | 1 |
36 | 19905 | 1 |
37 | a6141115 | 1 |
38 | 63/815 | 1 |
39 | 11.535 | 1 |
40 | 7445 | 1 |
41 | 59.9±12.6 | 1 |
42 | 61.0+/-9.6 | 1 |
43 | 79.06 | 1 |
44 | range=1.57 | 1 |
45 | navigated=67 | 1 |
46 | 4.577 | 2 |
47 | 42,8±16,8 | 1 |
48 | 38.19+/-11.8 | 1 |
49 | 7108 | 1 |
50 | 5,018 | 1 |
51 | 39/68 | 1 |
52 | 46+/-9 | 1 |
53 | group-65-79 | 1 |
54 | 29/179 | 1 |
55 | range= | 1 |
56 | bdi= | 1 |
57 | λ= | 1 |
58 | copepoda | 4 |
59 | amphipoda | 3 |
60 | roc-area | 2 |
61 | mufa∶pufa | 1 |
62 | paga | 2 |
63 | idella | 4 |
64 | parabola | 4 |
65 | pe-formula | 12 |
66 | ptpb | 3 |
67 | 6a-c | 3 |
68 | hekc | 1 |
69 | 5'nc | 3 |
70 | 3.5h/d | 2 |
71 | n/d | 3 |
72 | cttad | 5 |
73 | fiber-guided | 1 |
74 | dead-band | 1 |
75 | quenching-method | 1 |
76 | 4.2±standard | 1 |
77 | prevalemce | 1 |
78 | transience | 2 |
79 | adjusted-prevalence | 1 |
80 | amino-terminal-propeptide | 1 |
81 | icd-code | 4 |
82 | updrs-change | 1 |
83 | range | 33,574 |
84 | ovitrelle | 1 |
85 | ofisoleucine | 1 |
86 | monohydrazone | 1 |
87 | ham-d-17-score | 2 |
88 | pulse-pressure | 1 |
89 | spate | 4 |
90 | d58-value | 2 |
91 | block-size | 1 |
92 | δmpef | 1 |
93 | athf | 1 |
94 | lv-sf | 2 |
95 | ≥39°c/102.2°f | 1 |
96 | -90mg/g | 1 |
97 | 25.2g | 1 |
98 | 9,3g | 1 |
99 | 1.7g | 1 |
100 | 9.68g | 1 |
101 | breakfast/fasting | 2 |
102 | +9.4/h | 1 |
103 | 0.1cc/kg/6h | 1 |
104 | teacdpph | 1 |
105 | or4th | 2 |
106 | δzbmi | 2 |
107 | deltari | 2 |
108 | sham-icsi | 2 |
109 | macti | 3 |
110 | bvwi | 8 |
111 | diklofenak | 1 |
112 | 1½h/week | 1 |
113 | checkbook | 1 |
114 | 1-hour/wk | 1 |
115 | 1mol/l | 1 |
116 | fs-pl | 3 |
117 | 2.6iu/week/kg/gram | 1 |
118 | 3-4cm | 1 |
119 | kin-com | 3 |
120 | ≈bottom | 1 |
121 | neotyphodium | 4 |
122 | synonym | 22 |
123 | skyscan | 18 |
124 | scion | 5 |
125 | funding*location | 1 |
126 | pre-oxidation | 2 |
127 | exponentiation | 1 |
128 | expression/phosphorylation | 1 |
129 | severity/duration | 1 |
130 | endothelisation | 1 |
131 | afferentation | 1 |
132 | 'evacuation | 1 |
133 | ergonomics-evaluation | 1 |
134 | /composition | 1 |
135 | bipartition | 1 |
136 | prospect-prevention | 1 |
137 | decaocto | 3 |
138 | 50p | 1 |
139 | delta-gap | 2 |
140 | energy-gap | 1 |
141 | mwtp | 2 |
142 | 41±2year | 1 |
143 | 31±5year | 1 |
144 | 36.6±1.7year | 1 |
145 | focr | 2 |
146 | synchroniser | 2 |
147 | cter | 3 |
148 | reflor | 1 |
149 | te/tm/tr | 1 |
150 | turtur | 2 |
151 | i2-values | 1 |
152 | 'analysis | 2 |
153 | 36.5±3.5weeks | 1 |
154 | 36.7weeks | 1 |
155 | nonintersections | 1 |
156 | teqs | 4 |
157 | 65±10years | 1 |
158 | 68±10years | 1 |
159 | 18-70years | 2 |
160 | 60±1years | 1 |
161 | 72±1years | 1 |
162 | 38±2years | 1 |
163 | 54±3years | 1 |
164 | 26.4years | 1 |
165 | 56.2±9.4years | 1 |
166 | 59±14years | 1 |
167 | 63.6years | 1 |
168 | 56-77years | 1 |
169 | 40.9years | 1 |
170 | suppleness | 2 |
171 | lsr=stiffness | 1 |
172 | intent-to-treat/time-to-loss | 1 |
173 | resistance/loss | 1 |
174 | survival/loss | 1 |
175 | teacabts | 2 |
176 | airbursts/impacts | 1 |
177 | areas/targets | 1 |
178 | beta-coefficients | 2 |
179 | patagonicus | 2 |
180 | glareolus | 2 |
181 | regulus | 1 |
182 | alexandrinus | 1 |
183 | htvs | 1 |
184 | mrtvs | 1 |
185 | depcat | 3 |
186 | na-salt | 2 |
187 | u-point | 2 |
188 | t-nnt | 3 |
189 | winquist | 1 |
190 | 1750-19950iu | 1 |
191 | taw | 1 |
192 | zmax | 4 |
193 | toe-box | 1 |
194 | 27.3±7.4y | 1 |
195 | 24.6±3.8y | 1 |
196 | vecuronium-delay | 1 |
197 | 'play | 7 |
198 | voltage-dependency | 2 |
199 | s_tudy | 1 |
200 | baricity | 6 |
201 | non-universality | 1 |
202 | bioavilaibility | 1 |
203 | dose/intensity | 2 |
204 | number/intensity | 1 |
205 | frequency/quantity | 2 |
206 | pmnt/epoxy | 2 |
207 | tfz | 2 |
208 | ‘paradigm’ | 1 |
209 | tizanidine® | 1 |
210 | biosilicate® | 2 |
211 | 0-120° | 1 |